We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-16.3%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
AUM
$47.3M
AUM Growth
-$10.1M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 96.23%
2 Communication Services 3.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.67B
$19.8M 41.77%
1,615,321
SPRO icon
2
Spero Therapeutics
SPRO
$73M
$11.1M 23.53%
1,376,968
SURF
3
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$8.69M 18.37%
4,645,453
SYBX
4
DELISTED
Synlogic
SYBX
$4.56M 9.64%
176,798
SNAP icon
5
Snap
SNAP
$9.01B
$1.78M 3.77%
150,160
COGT icon
6
Cogent Biosciences
COGT
$7.24B
$1.38M 2.91%
840,384

Similar funds

Atlas Venture Associates IX's Q1 2020 Portfolio in Review

As of Q1 2020, Atlas Venture Associates IX held 6 positions worth $47.3M, down 18% from $57.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2020: portfolio turnover was 0%. Atlas Venture Associates IX opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Communication Services.

  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $47.3M portfolio in Q1 2020.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q1 2020.
  • Atlas Venture Associates IX's portfolio value fell 18% quarter-over-quarter to $47.3M.

Based on Atlas Venture Associates IX's 13F filing for Q1 2020, filed 7 May 2020.